Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter and signaling molecule derived from the essential amino acid Tryptophan, with a distribution that defies the brain-centric narrative of psychiatry: approximately 95% of the body's serotonin is produced by enterochromaffin cells in the gut, with only about 5% synthesised centrally in the Raphe nuclei of the brainstem. This peripheral-dominant distribution reflects serotonin's ancient evolutionary role as a paracrine and endocrine mediator of gut motility, platelet aggregation, vascular tone, bone metabolism, and immune responses long before vertebrate nervous systems repurposed it as a neurotransmitter for mood regulation, social behaviour, and threat perception. Crucially, peripheral and central serotonin pools are functionally separate because serotonin cannot cross the blood-brain barrier β the brain must synthesise its own supply from Tryptophan that does cross the BBB.
In clinical psychoneuroimmunology, serotonin occupies a pivotal position because its synthesis sits at the intersection of nutrition, inflammation, and psychology. The Tryptophan from which serotonin is made is subject to intense competition: under inflammatory conditions, the enzyme IDO (indoleamine 2,3-dioxygenase) is upregulated by pro-inflammatory Cytokines such as IFN-Ξ³, TNF-Ξ±, and IL-6, diverting Tryptophan away from serotonin synthesis and into the kynurenine pathway. This tryptophan steal is now considered a primary mechanism linking chronic low-grade inflammation to Depression β not a hypothetical serotonin "chemical imbalance" but a measurable metabolic diversion driven by the immune system. Understanding this mechanism transforms the clinical approach: rather than merely supplementing serotonin reuptake inhibition with SSRIs, the cPNI practitioner asks why tryptophan is being diverted, and addresses the upstream inflammation that drives IDO activation.
Serotonin's 14 receptor subtypes (5-HT1 through 5-HT7, many with sub-variants) mediate an astonishing diversity of physiological effects β from anxiolysis and sleep promotion to nausea, gut peristalsis, vasoconstriction, platelet aggregation, and cortical excitation. This receptor diversity, combined with the separate peripheral and central pools, explains why serotonin-targeting drugs produce such varied (and often paradoxical) effects, and why a systems-level understanding of serotonergic signaling β encompassing gut, brain, immune, vascular, and endocrine dimensions β is essential for cPNI practice.
Serotonin synthesis is a two-step enzymatic process that begins with the essential amino acid Tryptophan, which must be obtained from the diet (rich sources include turkey, eggs, cheese, nuts, seeds, and fish). Tryptophan crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), where it competes with other large neutral amino acids (the branched-chain amino acids Leucine, isoleucine, and valine, as well as phenylalanine and Tyrosine). This competition is clinically significant: a high-protein meal increases all competing amino acids and may paradoxically reduce brain tryptophan uptake, while a carbohydrate-rich meal stimulates Insulin release, which drives branched-chain amino acids into muscle, reducing competition and increasing the ratio of tryptophan to competing amino acids at the BBB. This is one mechanistic explanation for carbohydrate craving in depression and seasonal affective disorder.
In the first and rate-limiting step, tryptophan hydroxylase (TPH) hydroxylates Tryptophan at the 5-position to produce 5-hydroxytryptophan (5-HTP). Two isoforms exist: TPH1 is expressed peripherally (primarily in enterochromaffin cells of the gut, but also in the pineal gland and immune cells) and TPH2 is expressed exclusively in central serotonergic neurons of the Raphe nuclei. Both isoforms are BH4-dependent, requiring tetrahydrobiopterin as an essential cofactor, along with molecular oxygen (O2) and non-haem iron (Fe2+). These are precisely the same cofactors required by tyrosine hydroxylase (the rate-limiting enzyme for Dopamine, noradrenaline, and Adrenaline synthesis) and by phenylalanine hydroxylase β a convergence with profound clinical implications. Any condition that depletes BH4, impairs iron availability, or creates Oxidative Stress (which oxidises BH4 to the inactive dihydrobiopterin, BH2) will simultaneously impair synthesis of serotonin, Dopamine, and the other catecholamines. Inflammation is the master disruptor here: pro-inflammatory cytokines drive Oxidative Stress that depletes BH4, while Hepcidin-mediated iron sequestration further limits the iron cofactor, creating a double hit on monoamine synthesis that explains the co-occurrence of depressed mood, anhedonia, fatigue, and cognitive impairment in inflammatory states.
In the second step, aromatic amino acid decarboxylase (AADC, also called DOPA decarboxylase) converts 5-HTP to serotonin (5-HT) using pyridoxal phosphate (Vitamin B6) as its cofactor. This is the same enzyme that converts L-DOPA to Dopamine in the catecholamine pathway, again underscoring the shared enzymatic machinery between these monoamine systems. AADC is not rate-limiting β it has excess capacity β meaning that supplementation with 5-HTP can bypass the TPH rate-limiting step and increase serotonin production directly, provided adequate Vitamin B6 is available.
Serotonin serves as the obligate precursor for melatonin synthesis, a pathway that occurs primarily in the pineal gland under the control of the suprachiasmatic nucleus (SCN) and the light-dark cycle. At night, when sympathetic input to the pineal gland increases (mediated by noradrenaline acting on beta-1 adrenergic receptors), the enzyme arylalkylamine N-acetyltransferase (AANAT, also called serotonin N-acetyltransferase) acetylates serotonin to produce N-acetylserotonin. This is the rate-limiting step for melatonin synthesis, and AANAT activity shows dramatic circadian variation β nearly undetectable during daytime, rapidly upregulated at night. N-acetylserotonin is then methylated by hydroxyindole-O-methyltransferase (HIOMT, also called acetylserotonin O-methyltransferase) to produce melatonin (N-acetyl-5-methoxytryptamine), using S-adenosylmethionine (SAMe) as the methyl donor. This pathway means that serotonin depletion β whether from tryptophan diversion via the kynurenine pathway, BH4 depletion, or inadequate tryptophan intake β will also impair melatonin production, linking inflammation to the Circadian rhythm disruption and sleep disturbances that are nearly universal in inflammatory and depressive conditions.
The gut is the body's largest serotonin factory. Enterochromaffin (EC) cells β specialised enteroendocrine cells scattered throughout the gastrointestinal mucosa β produce approximately 95% of the body's serotonin via TPH1. This gut serotonin acts locally as a paracrine signal to regulate intestinal peristalsis, secretion, and visceral sensation. Serotonin released from EC cells stimulates 5-HT3 and 5-HT4 receptors on intrinsic primary afferent neurons of the enteric nervous system, initiating the peristaltic reflex: 5-HT4 activation on ascending interneurons promotes contraction behind the bolus, while descending relaxation allows propulsion forward. Simultaneously, serotonin activates 5-HT3 receptors on vagal afferent nerve terminals, sending information about gut content, distension, and mucosal conditions directly to the nucleus tractus solitarius in the brainstem β a critical pathway in the gut-brain axis that allows gut serotonin to influence central functions including nausea, satiety, and mood without ever crossing the blood-brain barrier.
Gut serotonin also plays immunoregulatory roles. EC-derived serotonin modulates dendritic cell, macrophage, and T-cell function via multiple receptor subtypes. The gut microbiome profoundly influences serotonin production: certain bacterial species (particularly spore-forming Clostridia) promote serotonin synthesis by EC cells through production of short-chain fatty acids and other metabolites that upregulate TPH1 expression. Germ-free mice have approximately 60% less colonic serotonin than conventionally colonised mice, and colonisation restores serotonin levels. This microbiome-serotonin axis provides a mechanism by which dysbiosis can influence gut motility, visceral pain, and β via vagal afferents β central mood regulation.
Serotonin acts on 14 receptor subtypes organised into seven families (5-HT1 through 5-HT7), most of which are G-protein-coupled receptors with the notable exception of the 5-HT3 receptor, which is a ligand-gated ion channel:
5-HT1 family (Gi/Go-coupled, inhibitory): 5-HT1A receptors are among the most clinically important β they exist as both presynaptic autoreceptors on serotonergic cell bodies in the Raphe nuclei (where they provide negative feedback, reducing serotonin neuron firing) and as postsynaptic heteroreceptors in the Hippocampus, Prefrontal cortex, and Amygdala (where they mediate anxiolytic and antidepressant effects). The 5-HT1A autoreceptor desensitisation that occurs over 2-4 weeks of SSRIs treatment is thought to explain the delayed onset of antidepressant action. Buspirone is a partial 5-HT1A agonist used as an anxiolytic. 5-HT1B/1D receptors in cerebral blood vessels are the targets of triptans used in migraine.
5-HT2 family (Gq-coupled, excitatory): 5-HT2A receptors are highly expressed in the Prefrontal cortex (layer V pyramidal neurons) and are the primary target of psychedelic compounds (psilocybin, LSD, DMT). 5-HT2A activation increases cortical excitability, enhances glutamatergic transmission, and promotes neuroplasticity β mechanistically linked to the therapeutic effects of psychedelic-assisted therapy for Depression and PTSD. 5-HT2C receptors regulate appetite and energy balance (antagonism causes weight gain, explaining the metabolic effects of atypical antipsychotics).
5-HT3 (ligand-gated Na+/K+ ion channel): The only ionotropic serotonin receptor, expressed on vagal afferents and in the area postrema (chemoreceptor trigger zone). Mediates rapid depolarisation, nausea, and emesis. 5-HT3 antagonists (ondansetron) are first-line antiemetics for chemotherapy-induced nausea.
5-HT4 (Gs-coupled, excitatory): Expressed throughout the gastrointestinal tract on enteric neurons. Promotes gut motility, secretion, and is the target of prokinetic agents (prucalopride) used in chronic constipation. Also expressed in the hippocampus where it enhances memory.
5-HT6 and 5-HT7: 5-HT7 receptors are involved in Circadian rhythm regulation, thermoregulation, and are implicated in mood disorders.
Serotonergic signaling is terminated primarily by reuptake via the serotonin transporter (SERT, encoded by the SLC6A4 gene), which clears serotonin from the synaptic cleft back into the presynaptic terminal using a sodium-dependent co-transport mechanism. SERT is the primary target of SSRIs (selective serotonin reuptake inhibitors) and SNRIs. The SLC6A4 gene contains a well-studied polymorphism in its promoter region, the serotonin-transporter-linked polymorphic region (5-HTTLPR): the short (s) allele reduces SERT expression and has been associated β controversially β with increased vulnerability to Depression and Anxiety following stressful life events (the gene-environment interaction model). While the direct effect size is debated, meta-analyses consistently show that the short allele moderates the relationship between early life adversity and later psychopathology, which aligns with the cPNI emphasis on developmental origins of disease and adverse childhood experiences.
Once reuptaked, serotonin is either repackaged into synaptic vesicles by the vesicular monoamine transporter (VMAT2) or degraded by monoamine oxidase-A (MAO-A), a mitochondrial outer membrane enzyme that oxidatively deaminates serotonin to 5-hydroxyindoleacetaldehyde, which is then oxidised by aldehyde dehydrogenase to 5-hydroxyindoleacetic acid (5-HIAA). 5-HIAA is excreted in urine and serves as a clinical biomarker of whole-body serotonin turnover β elevated urinary 5-HIAA is a hallmark of carcinoid tumours (serotonin-producing neuroendocrine tumours), while low 5-HIAA in cerebrospinal fluid has been associated with impulsivity and suicidality.
Perhaps the most important concept regarding serotonin in cPNI is the competition between the serotonin synthesis pathway and the kynurenine pathway for their shared substrate, Tryptophan. Under normal conditions, approximately 95% of dietary tryptophan is metabolised through the kynurenine pathway (primarily in the liver via tryptophan 2,3-dioxygenase, TDO, which is induced by cortisol) and only about 1-2% is used for serotonin synthesis. During inflammation, the enzyme indoleamine 2,3-dioxygenase (IDO) β expressed in macrophages, dendritic cells, microglia, and many other cell types β is powerfully upregulated by IFN-Ξ³, TNF-Ξ±, and IL-6. IDO catalyses the same reaction as TDO (conversion of tryptophan to N-formylkynurenine), but it is expressed in extrahepatic tissues and is under immune rather than hormonal control. The result is a dramatic diversion of tryptophan away from serotonin synthesis and toward the kynurenine pathway β simultaneously depleting the substrate for serotonin (and downstream melatonin) production while generating neuroactive kynurenine metabolites including quinolinic acid (an NMDA receptor agonist and neurotoxin) and kynurenic acid (an NMDA receptor antagonist). This inflammation-driven tryptophan steal represents a fundamental reimagining of the "serotonin hypothesis" of depression: serotonin is not inherently deficient but is being actively diverted by an immune system that prioritises tryptophan's antimicrobial and immunoregulatory functions over its role in mood regulation. The clinical implication is transformative: addressing the upstream inflammation that drives IDO activation may be more effective than blocking serotonin reuptake with an SSRI.
The traditional "serotonin deficit" hypothesis of Depression β that depression results from insufficient serotonergic neurotransmission β has been progressively refined by cPNI and immunopsychiatry into a more nuanced model. Meta-analyses show that approximately one-third of patients with major depression have elevated inflammatory markers (CRP, IL-6, TNF-Ξ±), and these "inflamed" patients respond poorly to conventional SSRIs but may respond better to anti-inflammatory interventions. The mechanism is clear: inflammation depletes BH4 (required for TPH), activates IDO (diverting tryptophan to kynurenine), and generates neurotoxic metabolites (quinolinic acid) that damage serotonergic neurons. Addressing inflammation β through dietary interventions (anti-inflammatory Mediterranean-type diets, omega-3 fatty acids), lifestyle factors (physical activity, sleep optimisation, Circadian rhythm restoration), gut barrier repair, and removal of inflammatory triggers β can restore tryptophan availability for serotonin synthesis. Tryptophan-rich foods or 5-HTP supplementation may support serotonin synthesis but will be ineffective if IDO is actively diverting tryptophan β the inflammation must be addressed first.
Given that 95% of serotonin is in the gut, it is unsurprising that serotonergic dysfunction is central to irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. IBS-D (diarrhoea-predominant) is associated with elevated mucosal serotonin and increased SERT expression, while IBS-C (constipation-predominant) is associated with reduced serotonin availability. Post-infectious IBS β developing after gastroenteritis β involves EC cell hyperplasia and increased serotonin release, linking gut inflammation to altered motility via serotonergic mechanisms. 5-HT3 antagonists (alosetron) slow gut motility in IBS-D, while 5-HT4 agonists (prucalopride) enhance it in IBS-C. From a cPNI perspective, the gut-serotonin connection reinforces the importance of addressing gut barrier integrity (leaky gut), dysbiosis, and mucosal inflammation as interventions that influence both gut motility and β via vagal afferents and systemic tryptophan metabolism β central mood regulation.
Because serotonin is the obligate precursor for melatonin, any condition that impairs serotonin synthesis will also disrupt melatonin production and Circadian rhythm function. The clinical triad of inflammation, Depression, and sleep disturbance is mechanistically unified through the tryptophan-serotonin-melatonin axis: inflammation diverts tryptophan, reducing both serotonin (mood) and melatonin (sleep), while sleep disruption further amplifies inflammation β creating a vicious cycle. Interventions that support tryptophan availability (dietary protein timing, reducing inflammatory tryptophan diversion), provide direct serotonin precursors (5-HTP, taken in the evening), or restore circadian light-dark signaling (morning light exposure, evening light restriction) can interrupt this cycle at multiple points.